| Literature DB >> 31191451 |
Silvia De Padova1, Chiara Casadei2, Alejandra Berardi1, Tatiana Bertelli1, Alessia Filograna2, Maria Concetta Cursano3, Cecilia Menna2, Salvatore Luca Burgio2, Amelia Altavilla2, Giuseppe Schepisi2, Sabrina Prati2, Sandra Montalti2, Michal Chovanec3,4, Giuseppe Luigi Banna5, Luigi Grassi6, Michal Mego3,4, Ugo De Giorgi2.
Abstract
Testicular cancer is the most common tumor in young males aged 15-40 years. The overall cure rate for men with testicular cancer is >90%, so a huge number of these patients will become testicular cancer survivors. These people may feel some stress in the experience of diagnosis, treatment, and consequences that affects the quality of life, and during follow-up, especially when new issues and emotional distresses appear over time, such as late side-effects of treatments and emotional challenges including fear of tumor relapse, fertility and sexuality concerns, and social and workplace issues. The cancer experience has an impact not only on patients, but also on their relatives (e.g., spouses, parents, or siblings), who often have to assume a caregiving role for the duration of and following treatment for cancer. Moreover, the caregiver plays an important role in supporting a man with a testicular cancer, providing physical and emotional care. This review presents a summary of existing knowledge regarding the impact and the burden of testicular cancer on caregivers.Entities:
Keywords: cancer; caregiver; long-term survivors; patients; testicular
Year: 2019 PMID: 31191451 PMCID: PMC6546807 DOI: 10.3389/fendo.2019.00318
Source DB: PubMed Journal: Front Endocrinol (Lausanne) ISSN: 1664-2392 Impact factor: 5.555
Therapeutic strategies, clinical complications, and correlation with QoL.
| Seminoma | I | Single agent Carboplatin (AUC7 for 1 cycle) or RT (20 or 25 Gy) | Myelotoxicity Fatigue | Low risk | Relapsed/Refractory TC | VeIP (4 cycles) or TIP (4 cycles) or HDCT ± RT | Myelotoxycity Fatigue Alopecia Vomiting Neurotoxicity Infertility Cardiovascular toxicity Pulmonary toxicity Solid secondary tumors Leukemia | High risk |
| IIA | RT (30 Gy) | Fibrosis | Low risk | |||||
| IIB | BEP (3 cycles) or EP (4 cycles) or RT in selected non-bulky cases | Myelotoxycity Fatigue Alopecia Vomiting Neurotoxicity Infertility Pulmonary toxicity Solid secondary tumors Leukemia | Intermediate risk | |||||
| IIC, III | BEP (3 or 4 cycles) | |||||||
| Non-seminoma | I | Surveillance or BEP (1 cycle) or RPLND | If BEP: Myelotoxicity Fatigue Vomiting Alopecia | Intermediate risk | ||||
| II, IIIA | BEP (3 cycles) or EP (4 cycles) or Nerve-sparing RPLND | Myelotoxycity Fatigue Alopecia Vomiting Neurotoxicity Infertility Pulmonary toxicity Solid secondary tumors Leukemia | Intermediate risk | |||||
| IIIB, IIIC | BEP (4 cycles) or VIP (4 cycles) |
RT, radiotherapy; BEP, Bleomycin, Etoposide, and Cisplatin; EP, Etoposide and Cisplatin; RPLND, retroperitoneal lymph-node dissection; VIP, Etoposide, Ifosfamide, and Cisplatin; VeIP, VeIP Vinblastine, Ifosfamide, Cisplatin; TIP, Paclitaxel, Ifosfamide, and Cisplatin; HDCT, high dose chemotherapy. Stage and primary treatment according to NCCN guidelines version 1.2019.
Graphical AbstractFactors influencing Caregiver emotional burden in TC patients.
Main psychological issues in TC caregivers.
| Need of information |
| Anxiety |
| Depression |
| Inadequacy |
| Lack of practical and emotional support |
| Risk of infertility |
| Sexual difficulties |
Differences in emotional burden between TC patients and their caregivers.
| Anxiety | 30–50 ( | 19–34 ( |
| Depression | 12–59 ( | 10–25 ( |